NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BETA · data 2026-10-31
Beta Drugs Ltd.
In plain words
Price: 36.0% below its 52-week high of ₹2,807.9.
Delivery: 38.8% of traded shares were kept for delivery over the last 10 sessions, against 49.2% over the last 60.
Latest results: a net profit of ₹20 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹444 cr |
| Net profit (last 12 months) | ₹52 cr |
| Sales growth, 3 years (yearly) | 19.2% |
| Profit growth, 3 years (yearly) | 10.5% |
At a glance
Promoters 58.9% (-7.8 pts in a year), pledged 0.0%, institutions 7.8%.
P/E 36.9, P/B 4.6, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 18.8%, ROCE 16.6%, operating margin 16.7%: how much profit it earns on the money it uses.
Debt/equity 0.62, Profit growth 10.5% and sales growth 19.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (18.8%).
- Promoters cut their holding by 7.8 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
BETA Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹137.49 crore, up 9.5% QoQ.
Net profit was ₹20.02 crore, up 16.6% QoQ.
Operating margin was 22%.
EPS was ₹16.59, up 12.2% QoQ.
BETA के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹137.49 करोड़; पिछली तिमाही की तुलना में 9.5% की बढ़त।
शुद्ध मुनाफ़ा: ₹20.02 करोड़; पिछली तिमाही की तुलना में 16.6% की बढ़त।
ऑपरेटिंग मार्जिन: 22%।
EPS: ₹16.59; पिछली तिमाही की तुलना में 12.2% की बढ़त।
BETAના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹137.49 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 9.5% વધારો.
ચોખ્ખો નફો: ₹20.02 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 16.6% વધારો.
ઓપરેટિંગ માર્જિન: 22%.
EPS: ₹16.59; ગયા ક્વાર્ટરની સરખામણીએ 12.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
18/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 13/30: Delivery 32.4% over the last 20 sessions vs 50.1% in the 40 before (0.65x); shares delivered per day 1.88x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 22 Oct 26Results Q2 FY27 results: net profit ₹20 cr +13.8% next session
- 20 Jul 26Results Q1 FY27 results: net profit ₹17.2 cr +11.2% next session
- 14 May 26Results Q4 FY26 results: net profit ₹9.1 cr -10.2% next session
- 14 Feb 26Results Q3 FY26 results: net profit ₹8.5 cr -17.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹137 cr | ₹20 cr | — | 22.0% | 16.59 |
| Jun 2026 | ₹126 cr | ₹17 cr | — | 21.8% | 14.78 |
| Mar 2026 | ₹94 cr | ₹9 cr | — | 18.8% | 8.93 |
| Dec 2025 | ₹87 cr | ₹9 cr | — | 19.5% | 8.4 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 58.91% | 59.10% | 64.63% | 64.90% |
| Foreign institutions (FII) | 1.37% | 1.02% | 1.16% | 1.14% |
| Domestic institutions (DII) | 6.45% | 6.23% | 2.15% | 1.90% |
| Mutual funds | — | 0.00% | 0.00% | 0.00% |
| Retail investors | 13.19% | 12.84% | 13.25% | 13.06% |
| Number of shareholders | 10,145 | 7,359 | 4,736 | 3,694 |
Common questions
What was Beta Drugs Ltd.'s latest quarterly profit?
Beta Drugs Ltd. reported a net profit of ₹20 cr for the quarter ended Sept 2026, on revenue of ₹137 cr.
How much do promoters hold in Beta Drugs Ltd.?
Promoters held 58.91% of Beta Drugs Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Beta Drugs Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.62.
What is Beta Drugs Ltd.'s P/E ratio?
About 36.9, based on the last 12 months' earnings and a price of ₹1,798.4 (data 2026-10-31).
What is the 52-week high and low of Beta Drugs Ltd.?
The 52-week high is ₹2,807.9 and the 52-week low is ₹990.1.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Beta Drugs Ltd. | ₹1,798.4 | ₹2,000 cr | 36.9 | 4.6 | 18.8% | 16.6% | 0.62 | -4.8% |
| Sakar Healthcare Ltd | ₹944.8 | ₹2,074 cr | 49 | 6.1 | 10% | 12.4% | 0.17 | +167.0% |
| Hester Biosciences Limited | ₹2,289.3 | ₹1,956 cr | 14.3 | — | 16.5% | 13% | 0.54 | +40.7% |
| Indoco Remedies Limited | ₹208.3 | ₹1,923 cr | 60.1 | 1.9 | -9.7% | -2% | 1.15 | -25.0% |
| Panacea Biotec Limited | ₹313.25 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -29.8% |
| Windlas Biotech Ltd. | ₹876.1 | ₹1,810 cr | 28 | — | 12.2% | 13.5% | 0.06 | -8.4% |
Compare BETA with SAKAR in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BETA in NSE Scanner →